

The Toxicology of Aflatoxins



*Human Health,
Veterinary,
and
Agricultural
Significance*

Edited by

David L. Eaton
John D. Groopman

The Toxicology of Aflatoxins



This page intentionally left blank

The Toxicology of Aflatoxins

Human Health, Veterinary, and Agricultural Significance

Edited by

David L. Eaton

*Department of Environmental Health
School of Public Health and Community Medicine
and Institute for Environmental Studies
University of Washington
Seattle, Washington*

John D. Groopman

*Department of Environmental Health Sciences
School of Hygiene and Public Health
The Johns Hopkins University
Baltimore, Maryland*



ACADEMIC PRESS, INC.

A Division of Harcourt Brace & Company

San Diego New York Boston London Sydney Tokyo Toronto

Cover photograph: Photomicrograph of a porcine liver fed 0.8 mg aflatoxin/kg feed for 10 weeks. (Adapted from figure 16.2: courtesy of Doris M. Miller and David M. Wilson.)

This book is printed on acid-free paper. ∞

Copyright © 1994 by ACADEMIC PRESS, INC.

All Rights Reserved.

No part of this publication may be reproduced or transmitted in any form or by any means, electronic or mechanical, including photocopy, recording, or any information storage and retrieval system, without permission in writing from the publisher.

Academic Press, Inc.

1250 Sixth Avenue, San Diego, California 92101-4311

United Kingdom Edition published by

Academic Press Limited

24–28 Oval Road, London NW1 7DX

Library of Congress Cataloging-in Publication Data

The Toxicology of aflatoxins : human health, veterinary and
agricultural significance / edited by David L. Eaton, John D.
Groopman.

p. cm.

Includes index.

ISBN 0-12-228255-8

1. Aflatoxins--Toxicology. I. Eaton, David L. II. Groopman,
John D.

RA1242.A344T68 1993

615.9'52923--dc20

93-13269

CIP

PRINTED IN THE UNITED STATES OF AMERICA

93 94 95 96 97 98 BC 9 8 7 6 5 4 3 2 1

Contents

| | |
|--------------|------|
| Contributors | xvii |
| Preface | xxi |

Part I

Experimental Toxicology of Aflatoxins

1 ♦ Acute Hepatotoxicity of Aflatoxins

John M. Cullen and Paul M. Newberne

| | |
|---|----|
| History | 3 |
| Biological Activity—Acute Aflatoxicosis | 5 |
| Epidemiological Evidence | 5 |
| Nonhuman Evidence | 6 |
| Factors Affecting AFB ₁ Toxicity | 15 |
| Dietary and Nutrient Effects | 15 |
| Gender Effects | 19 |
| Glutathione | 19 |
| Ethanol | 20 |
| Other Environmental Factors | 20 |
| Immunocompetence | 21 |
| References | 21 |

2 ♦ Biochemical Mechanisms and Biological Implications of the Toxicity of Aflatoxins as Related to Aflatoxin Carcinogenesis

Bill D. Roebuck and Yulia Y. Maxuitenko

| | |
|--|----|
| Acute and Chronic Toxicity of Aflatoxins | 27 |
| <i>In Vivo</i> Systems | 28 |
| <i>In Vitro</i> Systems | 31 |
| Mechanisms of Toxicity | 33 |
| Histopathological Observations | 34 |
| Biochemical Observations | 34 |

| | |
|---|----|
| Enhancement of Toxicity | 35 |
| Inhibition of Toxicity | 36 |
| Role of Acute and Chronic Toxicity in Carcinogenesis | 36 |
| Increased Cell Proliferation | 37 |
| Cell Replication in Carcinogenesis | 37 |
| Selection Pressure for Focal Growth | 38 |
| Cell Replication in Response to Aflatoxins | 39 |
| Implications of Aflatoxin Toxicity for Hepatic Carcinogenesis | 40 |
| References | 41 |

3 ❖ Biotransformation of Aflatoxins

David L. Eaton, Howard S. Ramsdell, and Gordon E. Neal

| | |
|--|----|
| Introduction | 45 |
| Biotransformation and Aflatoxin Toxicity | 45 |
| Detoxification Pathways | 46 |
| Biotransformation as a Determinant of Susceptibility to Aflatoxin Toxicity | 47 |
| Oxidation | 47 |
| Epoxidation | 47 |
| Hydroxylation | 50 |
| O-Demethylation | 51 |
| AFB(G) _{2α} Formation | 51 |
| Enzymology of Aflatoxin Oxidations | 52 |
| Reduction | 57 |
| Conjugation | 57 |
| Glutathione Conjugation of Epoxide | 57 |
| Glucuronidation of Hydroxylated Derivatives | 59 |
| Integration of Aflatoxin Biotransformation Pathways | 60 |
| Competing Pathways: Activation versus Inactivation | 60 |
| Kinetic Considerations | 62 |
| Factors Affecting Aflatoxin Biotransformation | 62 |
| Dietary Factors | 63 |
| Drug Treatments | 64 |
| Summary | 65 |
| References | 65 |

4 ❖ Pharmacokinetics and Excretion of Aflatoxins

Dennis P. H. Hsieh and Jeffrey J. Wong

| | |
|--------------------------------------|----|
| Introduction | 73 |
| Absorption | 74 |
| Absorption after Oral Administration | 74 |
| Absorption in the Small Intestines | 75 |

| | |
|--|----|
| Gastrointestinal Metabolism | 76 |
| Reabsorption of Aflatoxin B ₁ Conjugates | 78 |
| Distribution | 78 |
| Blood Time–Concentration Profiles and Compartment Analyses | 78 |
| Concentration in the Liver and the Kidney | 79 |
| Biotransformation | 81 |
| Excretion | 81 |
| Biliary Excretion | 82 |
| Urinary Excretion | 82 |
| Excretion through Milk | 84 |
| References | 85 |

5 ♦ Nonhepatic Disposition and Effects of Aflatoxin B₁

Roger A. Coulombe, Jr.

| | |
|-------------------------|----|
| Introduction | 89 |
| Respiratory System | 89 |
| Renal System | 92 |
| Gastrointestinal System | 93 |
| Nervous System | 94 |
| Reproductive System | 95 |
| Immune System | 96 |
| Miscellaneous | 97 |
| Summary | 97 |
| References | 98 |

6 ♦ Carcinogenicity of Aflatoxins in Nonmammalian Organisms

Jerry D. Hendricks

| | |
|--|-----|
| Introduction | 103 |
| Nonmammalian Animals Other than Salmonid Fishes | 104 |
| Birds | 104 |
| Reptiles | 106 |
| Amphibians | 106 |
| Nonsalmonid Fishes | 107 |
| Salmonid Fishes | 109 |
| Introduction and Species Sensitivity | 109 |
| Metabolism of AFB ₁ in Rainbow Trout | 112 |
| Development of Alternative Exposure Routes for Rainbow Trout | 117 |
| Carcinogenicity of Aflatoxin Metabolites in Rainbow Trout | 120 |
| Effects of Promoters on AFB ₁ Carcinogenesis in Rainbow Trout | 124 |
| Aflatoxin-Initiated Tumor Pathology | 126 |
| Summary | 127 |
| References | 127 |

7 ❖ Role of Aflatoxin DNA Adducts in the Cancer Process

George S. Bailey

| | |
|--|-----|
| Aflatoxin B ₁ Covalent Binding to DNA <i>in Vivo</i> | 137 |
| DNA Adducts Formed | 137 |
| Target Organ and Species Specificity | 138 |
| Dose–Response | 139 |
| Repair and Persistence of Aflatoxin B ₁ –DNA Adducts: | |
| Mechanisms of Adduct Loss | 139 |
| Nonrandom Genomic Damage by Aflatoxins | 141 |
| Influence of Local Chromatin Structure | 141 |
| Local DNA Sequence Effects | 141 |
| Comparison among Aflatoxins | 142 |
| Molecular Dosimetry and Proto-Oncogene Activation in Experimental Animal Tumorigenesis | 142 |
| AFB ₁ Dosimetry in Higher and Lower Vertebrates | 142 |
| Tumor-Initiating Potency of Adducts from Various Aflatoxins | 143 |
| Activated <i>c-ras</i> Proto-Oncogenes in Aflatoxin-Initiated Hepatic Tumors | 145 |
| Summary | 146 |
| References | 146 |

8 ❖ Mechanisms by Which Aflatoxins and Other Bulky Carcinogens Induce Mutations

Edward L. Loechler

| | |
|---|-----|
| Introduction | 149 |
| Studies on Individual Adducts of Bulky Mutagens/Carcinogens | 151 |
| Aminofluorescence–C8–Guanine | 151 |
| (+)-Anti-benzo[<i>a</i>]pyrene– <i>N</i> ² -Guanine | 152 |
| <i>cis</i> -Diamminedichloroplatinum {D(ApG)} | 152 |
| <i>cis</i> -Diamminedichloroplatinum {D(GpG)} | 152 |
| 2-Acetylaminofluorene–C8–Guanine | 152 |
| Additional Comments | 153 |
| Can DNA Sequence Context Influence Mutations Induced by Bulky Adducts? | 153 |
| Sequence Context and AFB ₁ Mutagenesis | 154 |
| Aflatoxin B ₁ Mutagenesis in Human Cells and in Tumors | 155 |
| Sequence Context and <i>O</i> ⁶ -Benzylguanine Mutagenesis | 156 |
| Sequence Context and (+)-Anti-benzo[<i>a</i>]pyrene Diol Epoxide Mutagenesis | 157 |
| Sequence Context and Mutagenesis with Benzo[<i>c</i>]phenanthrene Diol Epoxides | 159 |
| How Mutagenic Specificity Might Be Controlled by Sequence Context | 163 |
| Possible Mechanisms of Mutagenesis by Bulky Adducts | 165 |
| Introduction | 165 |
| Adduct-Induced Base Tautomerization | 166 |
| Adduct-Induced Base Ionization | 166 |
| Adduct-Induced Base Rotation | 167 |

| | |
|---|-----|
| Adduct-Induced Base Wobble | 167 |
| Noninformational Lesions | 167 |
| Does AFB ₁ Induce G→A Mutations via Adduct-Induced Base Ionization? | 168 |
| Misinformational Compared with Noninformational Mechanisms of Mutagenesis | 169 |
| Conclusions | 172 |
| References | 173 |

9 ♦ Aflatoxin Carcinogenesis in the Context of the Multistage Nature of Cancer

Yvonne P. Dragan and Henry C. Pitot

| | |
|---|-----|
| Historical Perspective on Development of Models of Experimental Carcinogenesis | 179 |
| Continual Carcinogen Administration | 179 |
| Less Than Lifetime Carcinogen Administration | 180 |
| Multistage Nature of Carcinogenesis | 180 |
| Aflatoxins as Carcinogens | 183 |
| Early Studies of Aflatoxin Carcinogenicity | 183 |
| Chronic Administration Studies of Aflatoxin Carcinogenicity | 184 |
| Start/Stop or Discontinuous Administration of Aflatoxin | 185 |
| Multistage Models of Aflatoxin-Induced Liver Cancer | 187 |
| Summary and Conclusions | 195 |
| References | 198 |

10 ♦ Nutritional Modulation of Aflatoxin Carcinogenesis

Adrianne E. Rogers

| | |
|-------------------------------------|-----|
| Introduction | 207 |
| Dietary Deficiency of Methyl Donors | 209 |
| Mechanisms of Action | 209 |
| AFB ₁ Toxicity | 216 |
| Other Considerations | 217 |
| Dietary Protein Deficiency | 218 |
| Dietary Fat | 219 |
| Vitamins and Minerals in the Diet | 220 |
| Vitamin A | 220 |
| Trace Minerals | 220 |
| Ethanol | 222 |
| Nonnutrient Food Components | 223 |
| Feed Restriction | 224 |
| Methyl-Supplemented Diet | 224 |
| Conclusion | 225 |
| References | 225 |

Part II

Human Carcinogenicity and Toxicity

11 ♦ Epidemiology of Aflatoxin-Related Disease

Andrew J. Hall and Christopher P. Wild

| | |
|-------------------------------------|-----|
| Introduction | 233 |
| Exposure Measurement | 234 |
| Food | 234 |
| Biological Samples | 236 |
| Mutation Spectra | 240 |
| Genetic Variation in Metabolism | 241 |
| Biological Effects of Exposure | 243 |
| Putative Disease Outcomes | 244 |
| Acute Hepatitis | 244 |
| Kwashiorkor | 245 |
| Reye's Syndrome | 245 |
| Hepatocellular Carcinoma | 246 |
| Others | 247 |
| Causality | 247 |
| Possible Future Research Strategies | 249 |
| Geographical Studies | 249 |
| Case Control Studies | 250 |
| Cohort Studies | 251 |
| Interventions | 252 |
| References | 253 |

12 ♦ Molecular Dosimetry Methods for Assessing Human Aflatoxin Exposures

John D. Groopman

| | |
|---|-----|
| Introduction | 259 |
| Internal Dose Measurements in Relation to Exposure Measurements | 262 |
| Urinary Markers | 262 |
| Internal Dose Markers in Milk | 263 |
| Free Aflatoxins in Blood | 264 |
| Markers of Biologically Effective Dose | 264 |
| Experimental Animal Studies | 264 |
| Human Studies | 269 |
| Molecular Dosimetry for Markers of Susceptibility | 272 |
| Markers of Early Biological Effect | 273 |
| Epidemiological Studies | 274 |
| Future Prospects | 275 |
| References | 276 |

13 ♦ Strategies for Chemoprotection against Aflatoxin-Induced Liver Cancer

Thomas W. Kensler, Elaine F. Davis, and Mary G. Bolton

| | |
|--|-----|
| Introduction | 281 |
| Factors Affecting Experimental AFB ₁ Hepatocarcinogenesis | 282 |
| Chemoprotection in the Rat | 282 |
| Chemoprotection in the Rainbow Trout | 288 |
| Chemoprotection against Aflatoxin Toxicities in Domestic Animals | 290 |
| Clinical Considerations for Chemoprotection in Humans | 291 |
| Identifying Target Populations for Interventions | 291 |
| Criteria for Selecting Chemoprotective Agents | 293 |
| Development of Intermediate Biomarkers | 295 |
| Conclusions | 300 |
| References | 301 |

Part III

Agricultural and Veterinary Problems

14 ♦ Factors Affecting *Aspergillus flavus* Group Infection and Aflatoxin Contamination of Crops

David M. Wilson and Gary A. Payne

| | |
|--|-----|
| Introduction | 309 |
| Aflatoxigenic Fungi | 310 |
| Taxonomy | 310 |
| Inoculum Sources | 310 |
| Aflatoxin Production: Aflatoxins B ₁ , B ₂ , G ₁ , and G ₂ | 312 |
| Factors Affecting <i>Aspergillus flavus</i> Group Inoculum and Initial Colonization | 313 |
| Corn | 314 |
| Peanut | 315 |
| Cottonseed | 316 |
| Conditions Affecting <i>Aspergillus flavus</i> Invasion, Growth, and Aflatoxin Accumulation | 316 |
| Corn | 317 |
| Peanut | 319 |
| Cottonseed | 320 |
| Aflatoxin Contamination of Stored Products | 321 |
| Summary | 321 |
| References | 322 |

15 ❖ Mycological Aspects of Aflatoxin Formation

Deepak Bhatnagar, Thomas E. Cleveland, and Peter J. Cotty

| | |
|--|-----|
| Introduction | 327 |
| Field Biology of Aflatoxigenic Fungi | 328 |
| Aflatoxin Biosynthesis | 329 |
| Chemistry | 330 |
| Enzymes | 333 |
| Genetics | 333 |
| Intraspecific Variation | 336 |
| Interference with Aflatoxin Biosynthesis | 337 |
| Biotic | 337 |
| Environment | 337 |
| Host Plant Resistance | 338 |
| Chemical or Biochemical | 339 |
| Conclusion | 340 |
| References | 340 |

16 ❖ Veterinary Diseases Related to Aflatoxins

Doris M. Miller and David M. Wilson

| | |
|-----------------------------------|-----|
| Introduction | 347 |
| Clinical Signs | 348 |
| Pathology | 349 |
| Clinical Pathology | 356 |
| Immune System | 356 |
| Other Diseases | 358 |
| Aflatoxin Intake and Disease Risk | 359 |
| Conclusions | 360 |
| References | 360 |

17 ❖ Aflatoxins in Milk

Hans P. van Egmond

| | |
|--|-----|
| Introduction | 365 |
| Conversion of Aflatoxin B ₁ to Aflatoxin M ₁ | 366 |
| At High Aflatoxin Levels | 366 |
| At Low Aflatoxin Levels | 367 |
| Conclusion | 368 |
| Toxicology | 368 |
| Short-Term Toxicity Studies | 369 |
| Chronic Toxicity Studies | 369 |
| Conclusion | 370 |

| | |
|--|-----|
| Analysis | 371 |
| Extraction and Clean-Up | 371 |
| Ultimate Separation and Determination | 372 |
| Reference Materials | 374 |
| Conclusion | 374 |
| Regulation and Occurrence | 375 |
| Regulation | 375 |
| Occurrence of Aflatoxin M ₁ in Milk | 375 |
| Conclusion | 377 |
| Stability and Degradation | 377 |
| Fate of AFM ₁ during Processing of Milk | 377 |
| Degrading of AFM ₁ in Milk | 378 |
| Conclusion | 379 |
| References | 380 |

18 ♦ Approaches to Reduction of Aflatoxins in Foods and Feeds

Timothy D. Phillips, Beverly A. Clement, and Douglas L. Park

| | |
|--|-----|
| Introduction | 383 |
| Aflatoxin Reduction Strategies | 384 |
| Food and Feed Processing | 384 |
| Biocontrol and Microbial Inactivation | 387 |
| Structural Degradation Following Chemical Treatment | 388 |
| Reduction in Bioavailable Aflatoxin by Selective Chemisorption | 394 |
| Conclusions | 398 |
| References | 399 |

Part IV Analytical Identification of Aflatoxins

19 ♦ Recent Methods of Analysis for Aflatoxins in Foods and Feeds

Mary W. Trucksess and Garnett E. Wood

| | |
|--|-----|
| Introduction | 409 |
| Sampling and Sample Preparation | 410 |
| Solid-Phase Extraction | 411 |
| Thin-Layer Chromatography | 411 |
| Liquid Chromatography | 413 |
| Immunochemical Methods | 416 |
| Methods for Aflatoxin M ₁ Detection in Milk and Milk Products | 420 |

| | |
|---|-----|
| Confirmation of Identities of the Aflatoxins | 421 |
| Automation | 424 |
| Safety Issues in Handling Moldy Grains and Aflatoxins | 425 |
| Conclusions | 426 |
| References | 426 |

20 ❖ Problems Associated with Accurately Measuring Aflatoxin in Food and Feeds: Errors Associated with Sampling, Sample Preparation, and Analysis

Thomas B. Whitaker and Douglas L. Park

| | |
|--------------------------------------|-----|
| Introduction | 433 |
| Variation among Test Results | 434 |
| Sampling Variability | 436 |
| Subsampling Variability | 437 |
| Analytical Variability | 439 |
| Reducing Variability of Test Results | 440 |
| Designing Aflatoxin Testing Programs | 442 |
| Selecting Samples | 446 |
| Conclusions | 448 |
| References | 448 |

21 ❖ Development of Antibodies against Aflatoxins

Fun S. Chu

| | |
|---|-----|
| Introduction | 451 |
| Methods for Preparation of Aflatoxin–Protein Conjugates | 452 |
| Preparation of Aflatoxin Derivatives and Site of Attachment of Aflatoxin to Macromolecules | 452 |
| Methods of Conjugation | 455 |
| Production of Antibodies against Aflatoxins | 457 |
| Production of Polyclonal Antibodies | 457 |
| Production of Monoclonal Antibodies | 458 |
| Characterization of Antibodies against Aflatoxins | 459 |
| General Considerations | 459 |
| Specificity of Polyclonal Antibodies Obtained from Immunogens Prepared by Conjugation of the Cyclopentanone Ring Portion of Aflatoxin Molecule to Carrier Protein | 460 |
| Specificity of Monoclonal Antibodies Obtained from Immunogens Prepared by Conjugation of the Cyclopentanone Ring Portion of the Aflatoxin Molecule | 463 |
| Specificity of Antibodies Obtained from Immunogens Prepared by Conjugation of the Dihydrofuran Moiety of the Aflatoxin Molecule | 463 |
| Cross-Reactivity of Aflatoxin Antibodies with Macromolecule Adducts | 464 |

| | |
|---|-----|
| Use of Aflatoxin Antibodies in Various Investigations | 467 |
| Development of Immunoassay Protocols and Their Application for the Analysis of Aflatoxins in Foods and Feeds | 467 |
| Use of Immunochemical Methods to Monitor Aflatoxin Exposure in Humans and Animals | 476 |
| Summary and Concluding Remarks | 481 |
| References | 482 |

Part V

Economic and Regulatory Aspects of Aflatoxins

22 ❖ Human Risk Assessment Based on Animal Data: Inconsistencies and Alternatives

Nancy J. Gorelick, Robert D. Bruce, and Mohammad S. Hoseyni

| | |
|---|-----|
| Introduction | 493 |
| Comparison of Rodent and Human Data for Risk Assessment | 493 |
| Risk Assessment Based on Rat Data | 494 |
| Liver Cancer in Humans in the United States | 494 |
| Possible Explanation for the Differences between Predictions from Rodents and Observations in Humans | 495 |
| Use of Epidemiological Data as an Alternative to Animal Data for Assessing Human Risk | 502 |
| Review of Available Human Data | 502 |
| Potency Estimates Based on Human Data | 503 |
| Relative Risk Model | 504 |
| Summary | 507 |
| References | 508 |

23 ❖ Economic Issues Associated with Aflatoxins

Simon M. Shane

| | |
|--|-----|
| Introduction | 513 |
| Agronomic Aspects of Aflatoxins | 514 |
| Economic Effects of Aflatoxins in Domestic Animals | 516 |
| Economic Impact of Aflatoxins in Human Populations | 522 |
| References | 524 |

| | |
|-------|-----|
| Index | 529 |
|-------|-----|

This page intentionally left blank

Contributors



Numbers in parentheses indicate the pages on which the authors' contributions begin.

George S. Bailey (137), Department of Food Science and Technology, Oregon State University, Corvallis, Oregon 97331

Deepak Bhatnagar (327), United States Department of Agriculture, Agricultural Research Service, Southern Regional Research Center, New Orleans, Louisiana 70179

Mary G. Bolton (281), Department of Environmental Health Sciences, School of Hygiene and Public Health, The Johns Hopkins University, Baltimore, Maryland 21205

Robert D. Bruce (493), Human and Environmental Safety Division, The Procter & Gamble Company, Miami Valley Laboratories, Cincinnati, Ohio 45239

Fun S. Chu (451), Food Research Institute, Department of Food Microbiology and Toxicology, University of Wisconsin, Madison, Wisconsin 53706

Beverly A. Clement (383), Department of Veterinary Public Health, College of Veterinary Medicine, Texas A & M University, College Station, Texas 77843

Thomas E. Cleveland (327), United States Department of Agriculture, Agricultural Research Service, Southern Regional Research Center, New Orleans, Louisiana 70179

Peter J. Cotty (327), United States Department of Agriculture, Agricultural Research Service, Southern Regional Research Center, New Orleans, Louisiana 70179

Roger A. Coulombe, Jr. (89), Department of Animal, Dairy, and Veterinary Science, Center for Environmental Toxicology, Utah State University, Logan, Utah 84322

John M. Cullen (3), Department of Microbiology, Parasitology, and Pathology, College of Veterinary Medicine, North Carolina State University, Raleigh, North Carolina 27606

Elaine F. Davis (281), Department of Environmental Health Sciences, School of Hygiene and Public Health, The Johns Hopkins University, Baltimore, Maryland 21205

- Yvonne P. Dragan** (179), McArdle Laboratory for Cancer Research, University of Wisconsin, Madison, Wisconsin 53706
- David L. Eaton** (45), Department of Environmental Health, HSB F-561, SC-34, University of Washington, Seattle, Washington 98195
- Nancy J. Gorelick** (493), Human and Environmental Safety Division, The Procter & Gamble Company, Miami Valley Laboratories, Cincinnati, Ohio 45239
- John D. Groopman** (259), Department of Environmental Health Sciences, School of Hygiene and Public Health, The Johns Hopkins University, Baltimore, Maryland 21205
- Andrew J. Hall** (233), Communicable Disease Epidemiology Unit, Department of Epidemiology and Population Sciences, London School of Hygiene and Tropical Medicine, University of London, London WC1E 7HT, United Kingdom
- Jerry D. Hendricks** (103), Department of Food Science and Technology, and the Marine Freshwater Biomedical Center, Oregon State University, Corvallis, Oregon 97331
- Mohammad S. Hoseyni** (493), Biometrics and Statistical Sciences, The Procter & Gamble Company, Cincinnati, Ohio 45241
- Dennis P. H. Hsieh** (73), Department of Environmental Toxicology, University of California, Davis, Davis, California 95616
- Thomas W. Kensler** (281), Department of Environmental Health Sciences, School of Hygiene and Public Health, The Johns Hopkins University, Baltimore, Maryland 21205
- Edward L. Loechler** (149), Department of Biology, Boston University, Boston, Massachusetts 02215
- Yulia Y. Maxuitenko** (27), Department of Pharmacology and Toxicology, Dartmouth Medical School, Hanover, New Hampshire 03756
- Doris M. Miller** (347), Athens Veterinary Diagnostic Laboratory, University of Georgia, Athens, Georgia 30602
- Gordon E. Neal** (45), MRC-Toxicology Unit, Medical Research Council Laboratories, University of Leicester, Leicester LE1 9HN, United Kingdom
- Paul M. Newberne** (3), Department of Pathology and, Mallory Institute of Pathology, Boston University School of Medicine, Boston, Massachusetts 02118
- Douglas L. Park** (383, 433), Department of Nutrition and Food Science, Food Toxicology Research Laboratory, University of Arizona, Tucson, Arizona 85721
- Gary A. Payne** (309), Department of Plant Pathology, North Carolina State University, Raleigh, North Carolina 27695
- Timothy D. Phillips** (383), Department of Veterinary Public Health, College of Veterinary Medicine, Texas A & M University, College Station, Texas 77843
- Henry C. Pitot** (179), McArdle Laboratory for Cancer Research, and Departments of Oncology and of Pathology, and Laboratory Medicine, University of Wisconsin, Madison, Wisconsin 53706

- Howard S. Ramsdell** (45), Department of Environmental Health, Colorado State University, Fort Collins, Colorado 80523
- Bill D. Roebuck** (27), Department of Pharmacology and Toxicology, Dartmouth Medical School, Hanover, New Hampshire 03755
- Adrienne E. Rogers** (207), Department of Pathology, Boston University School of Medicine, and Laboratory Medicine and Mallory Institute, Boston City Hospital, Boston, Massachusetts 02118
- Simon M. Shane** (513), Department of Epidemiology and Community Health, School of Veterinary Medicine, Louisiana State University, Baton Rouge, Louisiana 70803
- Mary W. Trucksess** (409), Center for Food Safety and Applied Nutrition, U.S. Food and Drug Administration, Washington, D.C. 20204
- Thomas B. Whitaker** (433), United States Department of Agriculture, North Carolina State University, Raleigh, North Carolina 27695
- Christopher P. Wild** (233), Unit of Mechanisms of Carcinogenesis, International Agency for Research on Cancer, World Health Organization, Lyon Cedex 08, France
- David M. Wilson** (309, 347), Department of Plant Pathology, Coastal Plain Experiment Station, University of Georgia, Tifton, Georgia 31793
- Jeffrey J. Wong** (73), Department of Toxic Substances Control, California Environmental Protection Agency, Sacramento, California 95812
- Garnett E. Wood** (409), Center for Food Safety and Applied Nutrition, U.S. Food and Drug Administration, Washington, D.C. 20204
- Hans P. van Egmond** (365), Laboratory for Residue Analysis, National Institute of Public Health and Environmental Protection, 3720 BA Bilthoven, The Netherlands

This page intentionally left blank

Preface



Over the past thirty years more than 8000 research articles describing the exposure, toxic effects, and mechanisms of action of aflatoxins have been published. The first published reports on the toxicology of aflatoxins pertained primarily to their acute effects, but by the end of the 1960s the carcinogenic potency of these agents was well established and became the focal point of much research. Indeed, the pioneering efforts of George Buchi, who first determined the structural characterization and synthesis of aflatoxins, and Gerald Wogan and Paul Newberne, who individually and collectively pioneered our understanding of the basic biochemistry, toxicology, and carcinogenicity of these agents, are outstanding examples of the application of basic science to a public health problem of global significance. Thus, by the end of the first decade of research on aflatoxins, it was suspected that these compounds were significant human and animal health hazards in various parts of the world. In 1969, Leo A. Goldblatt edited *Aflatoxin: Scientific Background, Control, and Implications*, published by Academic Press. This important book served as a source authority for many years on aflatoxins and provides many insights into the early studies of these agents.

In 1971, aflatoxins were reviewed in Volume 1 of the International Agency for Research on Cancer (IARC) Monographs on the Evaluation of Carcinogenic Risk of Chemicals to Man. That review was only eleven pages long in the monograph. It was concluded at that time that aflatoxins were possible human carcinogens, but the database was still extremely limited. Twenty years later these mycotoxins

were classified as Group I, known human carcinogens, and the summary of data published in 1993 in Volume 56 of the IARC Monographs is over 150 pages long. This explosion of information reflects the vast increase in information about the mechanisms of action of the aflatoxins over this period of time and reflects the large number of research scientists studying these toxins. The specific knowledge of the chemistry, biochemistry, toxicology, and epidemiology of aflatoxins is far greater than that for any other environmentally occurring chemical carcinogen. Indeed, it is possible to consider the studies of aflatoxin as a template for researching other environmental carcinogens. Toward this end, we have attempted to bring together as comprehensive a group of scientists as possible in assembling this book.

Part I focuses on the acute toxic effects of aflatoxins (Chapters 1 and 2), their biological disposition (Chapters 3–5), and specific aspects of aflatoxin carcinogenicity (Chapters 6–12). Included in these chapters are detailed reviews of the many important mechanistic aspects of aflatoxins that dictate individual and species susceptibility to aflatoxins. The hepatic biotransformation (Chapter 3), pharmacokinetics (Chapter 4), and genotoxin actions (Chapters 7 and 8) of aflatoxins as well as effects on nonhepatic tissues (Chapter 5), nonmammalian organisms (Chapter 6), and modulation by nutritional factors (Chapter 10) are described in detail. Finally, in this section the carcinogenesis of aflatoxin in animal models (Chapter 9) is discussed in the context of the multistage nature of chemical carcinogenesis.

Part II focuses more specifically on our current level of understanding of human exposures and effects of aflatoxins. The current status of the epidemiology of human aflatoxin exposures is detailed in Chapter 11, while Chapter 12 focuses on recent advances in the application of molecular biomarkers to the study of human cancer incidence in aflatoxin-exposed populations. Chapter 13 concludes with an enlightening review and discussion of potential avenues for human therapeutic and/or dietary interventions aimed at reducing liver cancer incidence in high risk populations, derived from our mechanistic understanding of aflatoxin carcinogenesis.

Part III examines agricultural and veterinary aspects of aflatoxin contamination of food and feed, including reviews on the fungal processes and factors that influence aflatoxin production by *Aspergillus* (Chapters 14 and 15), specific veterinary problems associated with aflatoxin contamination of feeds (Chapter 16), and the unique issues and concerns that arise from the excretion of aflatoxin M₁ in milk of dairy cows (Chapter 17). Lastly, current approaches for reducing the presence of aflatoxin contamination in animal feed and human food crops are discussed in detail (Chapter 18).

Part IV focuses on the complicated and difficult, yet extremely important, aspect of analysis of aflatoxins in food, feed, and biological samples. Chapter 19 reviews current approaches to the analytical determination of aflatoxins in complex matrices; Chapter 20 discusses strategies and problems in accurate sampling, preparation, and analysis of aflatoxins in food and feed; and Chapter 21

discusses the recent development of specific antibodies toward aflatoxin—methods that have found widespread use both in biomonitoring human populations and for analytical detection of aflatoxins in food and feed.

Part V concludes the book with a discussion of the important and sometimes controversial aspect of “quantitative risk assessment” of aflatoxins, which have profound regulatory implications, using either or both animal and human data (Chapter 22), and a discussion of the economic impacts of aflatoxin contamination that impact us all (Chapter 23).

David L. Eaton
John D. Groopman

This page intentionally left blank

Acknowledgments



We are grateful to all of the contributors for taking the time and effort to complete these chapters in a thorough yet timely manner. In addition to the individual contributions of each of our chapter authors, who are recognized leaders in their respective areas of specialization, many other scientists from around the world have contributed extensively to our understanding of aflatoxin biochemistry and toxicology. The lifelong contribution of Gerald Wogan to the study of aflatoxins should be especially noted, not only for his extensive and continuing publications in this area, but also for his role in training many of the top researchers in the field today. Indeed, many of the chapter authors in this book trained in Dr. Wogan's laboratory.

Many of us who are involved in the investigation of aflatoxins and other natural products find this work fascinating and compelling; however, we are also drawn to these compounds because of their real public health significance. Worldwide variations in daily exposure to aflatoxins are at least 5000-fold and, in some underdeveloped countries, human exposure can exceed 1 mg per day at certain times of the year. In other parts of the developed world, human exposure is much lower, less than 50 ng per day, but the veterinary and other economic consequences of aflatoxin exposure are still great. Given this situation it is hoped that the understanding of basic mechanisms of action of aflatoxins will lead to the design of effective prevention strategies for both the developed and developing world. Fortunately, the past support of many governments and their agencies

have provided the finances necessary to do this research and train the scientists with the skills to tackle these problems. In the future, as new environmental contaminants are discovered, the studies on aflatoxins will provide an important model for how mechanistically driven research can be used to devise and implement appropriate safety regulations to protect the public's health.

Finally, in addition to the many scientists who have provided the scientific substance for this book, we thank Azure Skye for her extensive and excellent administrative support in the development of this book from its inception. We are also grateful to the many people at Academic Press for their assistance, patience, and understanding in working with us to complete this book in a timely manner. We would be remiss without specifically acknowledging the research support provided by the National Institutes of Health, specifically the NCI and NIEHS, for research and training grants that have fostered our own interest in completing this book.

David L. Eaton
John D. Groopman

Part I



Experimental Toxicology of Aflatoxins

This page intentionally left blank